Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Setiptiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 known ✓ | P21728 | 7/20 | 0.76 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.76 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.76 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.76 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.76 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.76 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.76 |
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.50 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.50 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.50 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 6/20 | 0.76 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.76 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.76 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | DRD5 | P21918 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Setiptiline SCHEMBL29396748 | 1.00 | DRD1 (0.76) | DRD1DRD3CHRM2ADRA2ACHRM1 | |
| Setiptiline SCHEMBL29414110 | 0.87 | DRD1 (1.00) | DRD1DRD3CHRM2ADRA2ACHRM1 | |
| Setiptiline SCHEMBL211362 | 0.87 | DRD1 (1.00) | DRD1DRD3CHRM2ADRA2ACHRM1 | |
| Maleic Acid SCHEMBL167958 | 0.81 | DRD2 (0.59) | DRD1DRD3CHRM2ADRA2ACHRM1 | |
| Fumaric Acid SCHEMBL12467794 | 0.81 | DRD2 (0.59) | DRD1DRD3CHRM2ADRA2ACHRM1 | |
| SCHEMBL10728179 | 0.81 | DRD1 (0.86) | DRD1DRD3CHRM2ADRA2ACHRM1 | |
| SCHEMBL10730066 | 0.77 | DRD1 (0.69) | DRD1DRD3CHRM2ADRA2ACHRM1 | |
| Maleic Acid SCHEMBL11488022 | 0.75 | CYP3A4 (0.50) | DRD1DRD3CHRM2ADRA2ACHRM1 | |
| Fumaric Acid SCHEMBL11488028 | 0.75 | CYP3A4 (0.50) | DRD1DRD3CHRM2ADRA2ACHRM1 | |
| SCHEMBL12355565 | 0.73 | DRD1 (0.73) | DRD1DRD3CHRM2ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 537 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130237526-A1 | PHARMACEUTICAL COMPOSITION | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-09-12 | — | — | US | claimed |
| US-20060241102-A1 | Medicinal compositions | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-10-26 | — | — | US | claimed |
| EP-1655029-A1 | MEDICINAL COMPOSITIONS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-05-10 | — | — | EP | claimed |
| US-20260146047-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-28 | — | — | US | disclosed |
| US-12630534-B2 | 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists for the treatment of e.g. depression | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-19 | — | — | US | disclosed |
| US-12630509-B2 | Heterocyclic NMDA antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-19 | — | — | US | disclosed |
| EP-4727924-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO Pharmaceutical Co., Ltd. (JP) | 2026-04-22 | — | — | EP | disclosed |
| US-12600730-B2 | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-04-14 | — | — | US | disclosed |
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-02 | — | — | US | disclosed |
| US-20260092033-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-02 | — | — | US | disclosed |
| US-12590086-B2 | 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-03-31 | — | — | US | disclosed |
| EP-1369129-A1 | REMEDIES FOR DEPRESSION CONTAINING EP1 ANTAGONIST AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
| EP-1017370-B1 | MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs) | NYCOMED DANMARK APS (DK) | 2003-10-29 | — | — | EP | disclosed |
| US-6599529-B1 | Fast acting; sustained release | NYCOMED DANMARK A/S (DK) | 2003-07-29 | — | — | US | disclosed |
| EP-1109534-B1 | QUICK RELEASE PHARMACEUTICAL COMPOSITIONS OF DRUG SUBSTANCES | NYCOMED DANMARK AS (DK) | 2003-02-12 | — | — | EP | disclosed |
| EP-1109534-A1 | QUICK RELEASE PHARMACEUTICAL COMPOSITIONS OF DRUG SUBSTANCES | NYCOMED DANMARK A/S (DK) | 2001-06-27 | — | — | EP | disclosed |
| CN-1277550-A | Modified release multiple-unit compositions of non-steroidal anti-inflammatory drugs (NSAIDs) | NYCOMED DANMARK AS (DK) | 2000-12-20 | — | — | CN | disclosed |
| EP-1017370-A1 | MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs) | NYCOMED DANMARK A/S (DK) | 2000-07-12 | — | — | EP | disclosed |
| WO-2000015195-A1 | QUICK RELEASE PHARMACEUTICAL COMPOSITIONS OF DRUG SUBSTANCES | NYCOMED DANMARK A/S (DK) | 2000-03-23 | — | — | WO | disclosed |
| WO-1999012524-A1 | MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs) | NYCOMED DANMARK A/S (DK) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630509-B2 | Heterocyclic NMDA antagonists | GRIN1, GRIN3A, GRIN2B | DRD1 314/4885ADRA2A 1077/4885HTR1A 43/4885 |
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM2, CHRM4 | DRD1 194/4885ADRA2A 157/4885HTR1A 58/4885 |
| US-20260092033-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, MTNR1B | DRD1 105/4885ADRA2A 495/4885HTR1A 52/4885 |
| US-12590086-B2 | 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression | GPR139, OPRL1, GRIN2C | DRD1 205/4885ADRA2A 77/4885HTR1A 46/4885 |
| US-20260146047-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | HCRTR2, HCRTR1, NPY1R | DRD1 133/4885ADRA2A 544/4885HTR1A 129/4885 |
| US-20130237526-A1 | PHARMACEUTICAL COMPOSITION | ADORA2A, HTR2C, HTR5A | DRD1 67/4885ADRA2A 19/4885HTR1A 6/4885 |
| US-12630534-B2 | 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists for the treatment of e.g. depression | GPR139, OPRL1, GRIN2C | DRD1 162/4885ADRA2A 72/4885HTR1A 19/4885 |
| US-12600730-B2 | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | ABHD6, ABHD16A, HDHD5 | DRD1 2073/4885ADRA2A 1843/4885HTR1A 2808/4885 |
| US-20060241102-A1 | Medicinal compositions | ADORA2A, MAOA, HTR1A | DRD1 91/4885ADRA2A 19/4885HTR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.